ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Thanks auh2oman. I believe Q2 earnings will show Acth unit sales will continue showing year over year growth that it has shown since June 2022. ANIP's Corporate presentations shows that Aprils unit sales grew 25% over April 2022. With Mallinckrodt looking at a second bankruptcy filing, I believe you will see more of the increased sales coming to Corti over Acthar. This should help ANIP beat revenue and EPS estimates.

Analyst are estimating Q2 revenue 97.49M and EPS of $0.66, which, no doubt, is due to the guidance provided by ANIP. ANIP's revenue has grown at a 13% to 14% Quarter over Quarter rate over the last 4 quarters. I expect they will have another solid beating of revenue and EPS estimates for Q2. Hopefully they can keep the pace of growth going. If so, we will see another upward guidance and a big PPS pop upon earnings release. This could be further fueled by an announcement regarding the use of proceeds from the most recent offering.

GLTA